BioXcel Therapeutics (BTAI)
(Real Time Quote from BATS)
$3.48 USD
+0.51 (17.17%)
Updated Aug 6, 2025 03:12 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, BioXcel Therapeutics, Inc. has a market cap of $17.99M, which represents its share price of $2.97 multiplied by its outstanding shares number of 6.06M. As a small-cap company, BTAI's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BTAI 3.48 +0.51(17.17%)
Will BTAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTAI
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BTAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
Other News for BTAI
BioXcel Therapeutics announces publication on active ingredient in BXCL-501
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of ...
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session